傳艾美疫苗(06660.HK)國際發售開簿即獲超額認購
格隆匯9月26日丨艾美疫苗(06660.HK)發佈公告,於9月23日-9月28日招股,擬全球發售971.4萬股H股。每股發售價16.16港元,每手200股,預期H股將於10月6日(星期四)上午九時正(香港時間)在聯交所買賣。此次上市聯席保薦人爲高盛、中金公司、中信建投及麥格理。在同期發售的多家股票中,艾美疫苗表現尤爲突出,獲得機構及個人投資者積極認購。截至發稿,據有關人士瞭解,公司國際發售開簿就已獲超額認購,個人投資者融資申購倍數在同期發售的新股中一枝獨秀。據悉,此前艾美疫苗還曾吸引高瓴資本、正心谷、同創偉業等多家知名機構的投資。在產品上,作爲國內疫苗龍頭企業,艾美疫苗在研產品豐富,新冠疫情之前的全球疫苗之王13價肺炎結合疫苗(PCV13),以及mRNA新冠疫苗均已進入III期臨牀試驗。mRNA新冠疫苗(LVRNA009)在I期和Ⅱ期臨牀試驗中表現出良好的安全性和免疫原性。此外據瞭解,公司針對新冠病毒奧密克戎株的mRNA疫苗已申報CDE,力爭儘快推動其上市,以滿足迫切的市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.